Medios publishes investor presentation on European specialty pharma platform expansion

• Medios outlined its shift from a Germany-focused operator toward a European specialty pharma platform built on compounding and supply networks.
• 2026 revenue guidance set at EUR 2.1 billion to EUR 2.16 billion, supported by continued positive operating cash flow.
• H1 2026 revenue rose 8.4% to EUR 1.07 billion. EBITDA pre fell 5.1% to EUR 44 million. EBITDA pre margin slipped to 4.1%.
• Net income dropped 32.9% to EUR 8.5 million. Operating cash flow declined 52.1% to EUR 11.2 million. Free cash flow fell 85% to EUR 3.1 million.
• Ceban acquisition expanded the footprint across the Netherlands, Belgium, Spain. Platform includes 10 GMP facilities. Medsen chain totals 20 pharmacies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medios AG published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.